BioXcel Therapeutics (NASDAQ:BTAI) CEO Vimal Mehta Sells 19,419 Shares

Posted by Geri Gentry on May 23rd, 2026

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 19,419 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $1.09, for a total value of $21,166.71. Following the transaction, the chief executive officer directly owned 69,598 shares in the company, valued at $75,861.82. The trade was a 21.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BioXcel Therapeutics Stock Down 0.9%

Shares of NASDAQ:BTAI opened at $1.13 on Friday. BioXcel Therapeutics, Inc. has a twelve month low of $1.01 and a twelve month high of $8.08. The stock’s 50 day moving average is $1.23 and its 200-day moving average is $1.59. The firm has a market capitalization of $34.89 million, a price-to-earnings ratio of -0.20 and a beta of 0.31.

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.01). The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.38 million. Equities research analysts anticipate that BioXcel Therapeutics, Inc. will post -2.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BTAI shares. HC Wainwright lowered their price target on BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Wall Street Zen lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Rodman & Renshaw began coverage on BioXcel Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Monday, April 20th. Finally, Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.00.

Get Our Latest Stock Report on BioXcel Therapeutics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC grew its stake in shares of BioXcel Therapeutics by 78.5% during the 4th quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock worth $2,936,000 after acquiring an additional 807,139 shares during the period. Geode Capital Management LLC grew its stake in shares of BioXcel Therapeutics by 64.6% during the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock worth $330,000 after acquiring an additional 80,928 shares during the period. Jane Street Group LLC bought a new position in shares of BioXcel Therapeutics during the 4th quarter worth $204,000. State Street Corp grew its stake in shares of BioXcel Therapeutics by 19.9% during the 4th quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after acquiring an additional 10,500 shares during the period. Finally, Man Group plc bought a new position in shares of BioXcel Therapeutics during the 4th quarter worth $91,000. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

(Get Free Report)

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.